For example, the systemic treatment of advanced non-small cell lung cancer remained conventional chemotherapy for several decades until the emergence of TKI therapy following the discovery of several driver mutations including EGFR, ALK, ROS1, MET, RET, BRAF, and ERBB2/HER2 [1,17,18]. Here, ROS1 is linked to non-small cell lung carcinoma.